Observational Study on Hematological Adverse Drug Reactions (HADRs) from Hydroxyurea in Pediatric Patients with Sickle Cell Disease (SCD): Assessing Prevalence, Causality, Severity, Preventability, and Predictability, along with Clinical Management b

This study offers significant insights into the prevalence, clinical management, and outcomes of HADRs associated with hydroxyurea therapy in pediatric SCD patients. The findings underscore the need for proactive management approaches to optimize treatment outcomes and ensure patient safety.